Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Overview of attention for article published in Lancet Oncology, November 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

news: 1 news outlet
policy: 1 policy source
twitter: 16 X users

facebook: 3 Facebook pages
guideline: 3 clinical guideline sources

Readers on

mendeley: 236 Mendeley

So far, Altmetric has seen 16 X posts from 16 X users, with an upper bound of 122,328 followers.

RT @gantaisaku1105: 【卵巣がん】未治療の人で、標準的な化学療法にTKI阻害薬「オフェブ」の追加併用を選択することで、無増悪生存期間の延長が期待できる。試験では16.6ヵ月から17.2ヵ月に延長。〔Lancet Oncol〕 https://t.co/bCbN…

【卵巣がん】未治療の人で、標準的な化学療法にTKI阻害薬「オフェブ」の追加併用を選択することで、無増悪生存期間の延長が期待できる。試験では16.6ヵ月から17.2ヵ月に延長。〔Lancet Oncol〕 https://t.co/bCbNQ8KEZD

No survival data, but if you add this $$$ nintedanib to chemo, your ovarian ca progression will delay by 18 days!! https://t.co/aKZBaVBDiO

"Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12)" https://t.co/Fatm4Ki6gY

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 12 additional X posts.